Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples